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Immunoglobulin G (IgG) against food proteins has become the subject of much
discussion with regards to its role in adverse food reactions. An estimated 20% of the population
suffers from some type of food intolerance. Food sensitivity can present with a vast range of
symptoms and severities. Diet can have a substantial impact on the wellbeing of individuals with
diseases of the gastrointestinal tract, such as Crohn’s disease or ulcerative colitis. Incidentally,
these diseases have been associated with elevated levels of food-specific IgG as well an
increased likelihood of food sensitivity. The presence of food-specific IgG and food sensitivity in
individuals with digestive tracts that have been altered by ostomy surgery has not been
previously evaluated. Understanding the relationship between various disease states and the
presence of food-specific IgG could open the door to better understanding of food sensitivity and
the underlying mechanisms. Ostomates provide a particularly useful insight into the development
of food-specific IgG by illuminating the impact of different regions of the digestive tract on oral
tolerance and therefore the generation of food-specific IgG.
In this thesis, by assessing the presence of food-specific IgG in individuals with altered
digestive tracts, we have further explored the relationship between disease status, intestinal
permeation, and food sensitivity.
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CHAPTER 1. OSTOMY, INFLAMMATORY CONDITIONS OF THE
GASTROINTESTINAL TRACT, AND FOOD-SPECIFIC IgG: A REVIEW
1.1

INTRODUCTION
The majority of individuals show very little consideration when making decisions

regarding dietary composition (1). Often, any food will suffice so long as it is cheap, fast,
and available. Individuals with ailments related to the digestive tract, however, must
spend a significant amount of time to ensure their diets are properly managed. This is
frequently done to maintain health and avoid adverse symptoms that can be experienced
upon the consumption of specific foods.
Ostomates are individuals that undergo a bowel resection and must discharge bodily
waste from an artificial opening placed in or on the abdomen. Ostomates can have
tremendous difficulty adjusting their diets to ensure adequate nutrition and optimize
comfort (2, 3). Additionally, certain diseases of the gastrointestinal tract, such as Crohn’s
disease, ulcerative colitis, and eosinophilic esophagitis are linked to dietary intake (4, 5).
These diseases can cause significant distress if mismanaged. Unfortunately, the exact
way that these diseases develop is usually difficult to determine. One suggested
mechanism is immunoglobulin G (IgG) against specific food proteins.
In this study, I have compared levels of IgG to foods from ostomates to levels from
individuals with inflammatory diseases along the digestive tract. I will introduce
background regarding the different components of this project, which compares IgG
levels of ostomates to those of individuals with inflammatory diseases of the digestive
tract. In this review, I will describe ostomy-based gastrointestinal alteration, the role of
IgG in hypersensitivity, associations of food-specific IgG with food sensitivity, and
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recent findings of the efficacy of IgG-based elimination diets. Additionally, the review
will discuss background knowledge of biomarkers regarding immunocompetency via the
detection of total IgG and total IgA, as well as systemic inflammation via the detection of
serum calprotectin. This chapter will conclude by describing multiple inflammatory
diseases of the digestive tract. These diseases are examined in the following study, along
with current knowledge about their coincidence with food sensitivity to serve as a
comparative basis to those with ostomies.
1.2

OSTOMY
In the United States, between ~750,000 and ~1,000,000 individuals are living

with ostomies (6, 7). An ostomy is a surgical procedure that reroutes bodily waste from
its usual path toward an external collection system. The need for ostomy surgery can
occur for various reasons, including but not limited to cancer (colon cancer, cancer of the
cervix or endometrium, etc.), damage from radiation due to cancer treatment, the
escalation of a gastrointestinal disorder such as Crohn’s disease or ulcerative colitis, or
traumatic abdominal injury, such as gunshot (8-10).
Ostomates must learn to manage their diet and fecal output systems in order to
maintain a normal lifestyle. This is made difficult by the fact that ostomates suffer from
high rates of surgical complication, with reports ranging from 21-70% of ostomates
experiencing different types of complication including electrolyte abnormalities, renal
dysfunction, short bowel syndrome, parastomal hernia, dehydration, skin irritation, and
stomal prolapse, to name a few (11, 12).
One of the largest challenges presented to post-surgery ostomates is the
readaptation to food intake (13). At the time of the procedure, the majority of ostomates

12
are malnourished due to the diseases that made ostomy surgery necessary (13). Adequate
nourishment must also be carefully monitored after surgery, as significant portions of the
digestive tract are often removed. As such, the diet of ostomates often needs to be
substantially altered in order to manage nutrition and fecal output. These alterations, in
conjunction with food sensitivity, can limit the dietary options available to some
ostomates (12).
1.3

IGG AND OTHER BIOMARKERS OF FOOD SENSITIVITY
1.3.1

IgG and hypersensitivity

IgG is the most abundant antibody in the immune system and is the body’s main
defense against infection and disease (14). Of the four subclasses of IgG produced (IgG1,
IgG2, IgG3, IgG4), IgG1, IgG2, and IgG3 are the three most prevalent and they are all
involved in complement activation, effector cell recruitment, and opsonization (14).
Deficiencies in IgG can result in increased susceptibility to bacterial infection, especially
when accompanied by deficiency of another class of immunoglobulin (15). Additionally,
IgG can also play a role in immune hypersensitivity reactions.
Four types of immune hypersensitivity reactions are generally recognized. These
are denoted as reaction types I-IV and are differentiated based on their mechanism of
action. Type I hypersensitivity reactions are mediated by allergen-specific IgE and
always involve the degranulation of mast cells and basophils (16). These reactions are
immediate and often life-threatening. Type II hypersensitivity reactions are mediated by
IgG and IgM antibodies against cell antigens, which leads to cell destruction through
complement, cell degranulation, or phagocytosis (16). Type III hypersensitivity reactions
are also mediated by IgG and IgM, antibodies that can form complexes around both self-
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and non-self-antigens and accumulate in tissue. They can then cause damage by directing
immune responses inappropriately (16). Type IV hypersensitivity reactions are primarily
T-cell driven and are typically delayed from the time of exposure (16). Type III
hypersensitivity reactions are of particular interest to this review, as IgG complexes can
initiate complement cascades leading to inflammation (14).
Symptoms of hypersensitivity reactions vary substantially, although some are
commonly shared (17). These include tissue damage and inflammation. For many
hypersensitivity reactions, the exact mechanism of action remains debated or unknown,
which makes the task of disentangling symptoms and causes of the illness quite difficult.
Importantly, there is frequently contradicting ideas about the status of diseases with
poorly understood pathophysiology. This can make the classification of some
hypersensitivity reactions a subject of intense debate.
1.3.2

Food Sensitivity and IgG

It is estimated that 20% of the of people living in industrialized countries may
suffer from food intolerance or food allergies (18). In certain groups of people, this
number could be much higher. A cross-sectional study of 11,078 individuals indicated
that up to 70% of those affected with irritable bowel syndrome had food-related
symptoms (19). Because of the challenges associated with nutrition management, foodrelated immune interactions that can be managed by diet are of significant interest to
those investigating ways to improve wellness.
Typically, when food is consumed, proteins will be broken down into
oligopeptides and amino acids in the digestive tract. When contact with immune cells
occurs, these oligopeptides and amino acids may trigger either an immunotolerant effect
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or an inflammatory effect. The immunization response varies from food to food and from
person to person. The exact causes of the type of response created are currently not well
understood, however implicated factors include but are not limited to the intestinal
microbiota, intestinal inflammation, intestinal barrier disfunction, and pathogenic
infection (20-22). The lining of the gastrointestinal tract provides a barrier between
ingested antigens and the immune system. However, several mechanisms exist and allow
antigen sampling to take place. These mechanisms include goblet cell associated
passages, trans-epithelial dendrites, M cell sampling, and paracellular leak (23). When
antigens from food pass through the mucosa, the process of antigen uptake has an impact
on the immune response (23). Increased permeability of the gastrointestinal tract can
increase the number of antigens sampled, thereby increasing the likelihood of an altered
immune response (23, 24). Inflammation can increase the permeability of the digestive
tract lining (25). Tordesillas and Berin suggest that the inflammation can impact the
generation of a tolerance response to consumed antigens (26). In 2004, Aljada et al.
reported the evidence that food consumption is associated with a pro-inflammatory
immune response (27). The immunization response generated will have a substantial
impact on the severity of the reaction to the food. One possible pathway of food
sensitivity pathogenesis occurs by way of food-specific IgG.
Juchnowicz, et al. demonstrated that individuals with major depressive disorder
have significantly higher serum levels of food-specific IgG antibodies’ than healthy
controls, and that higher levels of food-specific IgG are correlated with gastric
complaints (28). Many studies have been done on Crohn’s disease and ulcerative colitis,
suggesting higher levels of food-specific IgG in Crohn’s disease patients than in controls
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(29-31). Frehn et al. described distinct IgG and IgA profiles against food and microbial
antigens when comparing inflammatory bowel disease patients to controls (32). Hvatum
et al. also found that IgG titers against food proteins were elevated in rheumatoid arthritis
patients (33). Additionally, Wilders-Trusching et al. reported elevated levels of foodspecific IgG associated with increased intima thickness and inflammation in obese
juveniles (34).
Food sensitivity is a topic that is subject to much discussion. However, the
growing body of literature continues to suggest that non-IgE mediated food sensitivity
may be at play.
1.3.3

IgG-guided elimination diets

Further evidence of the connection between food sensitivity and non-IgE
mediated hypersensitivity is supported by the growing amount of data on the utility of
elimination diets. One study found that a food elimination diet based on serum IgG
against food-specific proteins was effective in reducing symptoms of irritable bowel
syndrome in affected individuals (35). Another study by Xie et al. demonstrated that an
IgG elimination diet reduced migraines and irritable bowel syndrome symptoms in 60
affected individuals (36). In individuals with Crohn’s disease, stool frequency decreased,
and overall wellbeing increased when dietary interventions were taken based on foodspecific IgG testing results (31). An IgG-guided exclusion diet has also relieved
symptoms and improved quality of life for individuals with ulcerative colitis (37).
1.3.4

IgA and food sensitivity

IgA is the second most abundant immunoglobulin produced by the human
immune system. IgA is found primarily on the mucosal surfaces of the body, such as the
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nostrils, mouth, and digestive tract lining (38). On mucosal surfaces, secretory IgA
(SIgA) are secreted as dimers and transported to the mucosal surface through epithelial
cells (39). Like IgG, IgA plays a role in protection against infection. Unlike IgG, IgA also
plays a role in preventing antigens from coming into contact with the immune system.
This protective mechanism of IgA occurs through a unique process known as immune
exclusion, whereby SIgA prevents antigens from coming into contact with the immune
system by transporting antigens out of the lamina propria to the enterocyte surface (40).
Immune exclusion is also critical for the active maintenance of the commensal intestinal
microbiome (41). When bound to an antigen, IgA can downregulate immune system
functions such as chemotaxis, cytokine release, and IgG-mediated phagocytosis (42-44).
With these protective functions, it is not surprising that SIgA is frequently associated
with the presence of immune tolerance to orally acquired antigens, namely food. This
also led us to ask the question: how is oral tolerance impacted by the absence of SIgA?
Selective IgA deficiency occurs when an individual has drastically reduced, or
even undetectable levels of serum IgA (45). Most frequently, levels of other circulating
antibodies remain unaffected. Selective IgA deficiency is the most common primary
immunodeficiency, with an estimated prevalence varying geographically from 1:143 in
Saudi Arabia to 1:18,500 in Japan (45). It frequently remains undiagnosed, as up to 75%
of those infected may remain asymptomatic (46). The most common symptoms of
selective IgA deficiency are recurrent respiratory infections, presence of autoimmune
diseases, the development of gastrointestinal disorders such as ulcerative colitis and
Celiac disease, and food allergy (47). For many, the occurrence of these symptoms alone
is not indicative of a greater problem, thus many individuals remain undiagnosed.
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Previous studies have indicated an association between respiratory and food allergies, and
selective IgA deficiency. An Egyptian study found that of 100 individuals with food
allergy, 67% were IgA deficient (48). A study found that of 126 children in Brazil with
selective IgA deficiency, 46% suffered from either respiratory or atopic allergy (49).
Additionally, it was observed in Italy that 2.6% of individuals with selective IgA
deficiency were also diagnosed with Celiac disease (50). Two studies have been done
examining the presence of food-specific antibodies in individuals with selective IgA
deficiency— both of which indicated that IgA deficiency is associated with increased
levels of circulating IgG against foods (51, 52).
1.3.5

Calprotectin as a marker of inflammation

As mentioned above, it is often difficult to assess the extent and severity of
disease in individuals with inflammatory bowel diseases. Because the level of
inflammation is a key indicator to the severity of the disease, researchers have searched
for an indirect method by which to measure inflammation. Many have looked to
calprotectin.
When infection occurs, the host immune system will initiate an inflammatory
response to recruit immune cells for host defense. As part of the innate immune response,
neutrophils and macrophages are often the first cells recruited to the site of infection,
where they release calprotectin (53). Calprotectin is a calcium and zinc-binding protein
found in neutrophils and macrophages in the body. When released, calprotectin has
antibacterial properties, induces apoptosis, and aids in chemotaxis (54, 55). In individuals
with dysregulated inflammatory responses of the digestive tract, such as ulcerative colitis
and Crohn’s disease, levels of neutrophil recruitment are elevated (56). The calprotectin
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is released into the digestive tract and measured in feces. Today, fecal calprotectin is a
widely used biomarker to assess the severity of inflammatory bowel diseases (57, 58).
Fecal calprotectin is typically used for disease assessment in inflammatory bowel
diseases, as it can indicate inflammation by way of neutrophilic migration to the intestinal
lining.
In diseases such as rheumatoid arthritis and systemic lupus erythematosus
inflammation may not be localized to one specific region. In individuals with these
diseases, it has been found that elevated levels of serum calprotectin can be observed (59,
60). Serum calprotectin has also been shown to be a useful diagnostic tool for assessing
disease burden in patients with inflammatory bowel disease, as well as an indicator of
systemic inflammation (61-63).
1.4

INFLAMMATORY CONDITIONS OF THE GASTROINTESTINAL
TRACT
In order to establish a basis of the effects of inflammation on the generation of

food-specific IgG, we will introduce the following inflammatory conditions of the
digestive tract: periodontitis, eosinophilic esophagitis, duodenitis, appendicitis, Crohn’s
disease, and ulcerative colitis. In the following sections, a brief introduction of these
conditions will be given, and the present knowledge of food sensitivity in each disease
will be evaluated.
1.4.1

Periodontitis

Periodontitis is chronic inflammation of the periodontium due to microbial interactions in
the host oral cavity (64). Periodontitis is the sixth most common human disease, with an
estimated 45-50% of the global population being affected. (65). Periodontitis can begin in
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childhood but is most common in adult populations. There are currently four recognized
types of periodontitis: necrotizing, chronic, aggressive, and periodontitis as a
manifestation of systemic diseases (66). Symptoms of periodontitis can vary; however,
the effects frequently include the gums becoming red and bleeding. In later stages, the
gums can also pull away from the teeth and is associated with bone loss (67). One of the
primary causes is the buildup of microbial biofilms, known as plaque, on the surface of
the tooth. In individuals with periodontitis, a shift in the oral microbiota has been
observed from a gram-positive dominated population to a gram-negative dominated
population (68). This shift leads to changes in host immune responses to the oral
microbiota, which contributes to periodontitis symptoms including bone loss (69).
Periodontitis has been associated with several comorbidities, including diabetes,
cardiovascular disease, pancreatic cancer, and chronic obstructive pulmonary disease (7074). Treatments for periodontitis usually include the removal of plaque and buildup from
the tooth surface and require home-management of tooth health, i.e. brushing (75). In
recurring disease, additional therapeutic measures used include local or systemic
antibiotics and surgical intervention to aid in periodontium regeneration (76-78).
Several studies have shown that periodontitis can have an effect of IgE mediated
allergy, however none has been done so far on the incidence of IgG-mediated food
sensitivity (79, 80).
1.4.2

Eosinophilic esophagitis

Eosinophilic esophagitis is a recently recognized disease, which was first described in the
1990s (81). Since then, work has been done has been done to better characterize the
precise mechanisms of disease and clinical outcomes. Eosinophilic esophagitis is
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typically characterized by inflammation of the esophagus leading to difficulty swallowing
and food impaction. Other symptoms include chest pain, heartburn, nausea, and vomiting
(82). These symptoms are similar to those of gastroesophageal reflux disease (GERD)
and can be difficult to diagnose. Because of this, diagnosis of eosinophilic esophagitis
must be confirmed by observation of at least 15 eosinophils per high-power field in
esophageal biopsy tissue (83). The exact pathogenesis has been the subject of some
dispute. Environmental factors have been indicated in symptom development, and the
role of diet in eosinophilic esophagitis has been investigated since at least 1995, when it
was observed that an amino-acid diet managed symptoms until the reintroduction of food
(84-86). There have also been studies done which suggest that the esophageal
microbiome may have a role to play (87, 88).
In 15-43% of individuals, IgE mediated allergies have been observed, which has
led to the conclusion that IgE plays a crucial role in the development of eosinophilic
esophagitis (89). However, additional studies have shown elevated levels of IgG4 in
serum of patients, leading to the hypothesis that eosinophilic esophagitis is an IgG4
related disease (90). Moreover, in the same study, no beneficial response was seen when
anti-IgE therapy was introduced. In some cases, eosinophilic esophagitis has also been
shown to develop during food oral immunotherapy used to treat food allergies. It is well
established that specific foods are one of the most prevalent triggers in individuals with
eosinophilic esophagitis. (91, 92). The role of TH2 cells in pathogenesis has also been
investigated, with one research group finding elevated CD4+ TH2 cells in blood of
eosinophilic esophagitis patients when compared to controls after consumption of milk
(93). Methods of treating eosinophilic esophagitis currently include the administration of
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proton pump inhibitors, the implementation of diets which avoid food that trigger
symptoms, administration of corticosteroids, and esophageal dilation using endoscopic
balloons (94, 95).
1.4.3

Duodenitis

The duodenum is the first portion of the small intestine located immediately following
the stomach and is approximately 25-38 cm in length. When inflammation occurs in this
region, it is known as duodenitis. There are several diseases and incidents related to the
symptoms of duodenitis, including celiac disease, peptic duodenitis, inflammatory bowel
disease, autoimmune disease, allergy to soy and cow’s milk, and bacterial overgrowth
(96-100). Additionally, long term use of non-steroidal anti-inflammatory drugs can also
induce duodenal inflammation (101). Current treatments for duodenitis can vary greatly
and often hinge on the resolution of the primary disease.
No specific studies have been focused on the presence of food sensitivity in
individuals with duodenitis. Several of the conditions such as Celiac disease, which can
lead to duodenitis have been associated with food sensitivity (96).
1.4.4

Appendicitis

Inflammation of the appendix, or appendicitis, is one of the most common
gastrointestinal emergencies requiring surgery worldwide, with an estimated 7% of
individuals affected at some point in their lives (102). The exact cause of appendicitis is
unknown; however, it has been attributed to obstruction, infection, and environmental
triggers (103, 104). Studies have also confirmed that individuals with family members
affected by appendicitis have a three times higher risk of contracting the illness
themselves (105). Additionally, a study conducted on the appendicular microbiome of
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people with appendicitis identified that bacterial species not generally associated with the
human intestine were present (106). Treatment of appendicitis may vary, although
surgical removal of the appendix is the most common and effective management strategy.
Recently, antibiotic treatment of appendicitis has been studied, implying that it may be an
effective treatment (107).
At this time, no studies have been done on the relationship between appendicitis
and food sensitivity.
1.4.5

Inflammatory bowel disease

Inflammatory bowel diseases are chronic inflammatory conditions that are
mediated by T-cell disfunction in the gastrointestinal mucosa (108). The two major types
of inflammatory bowel disease are Crohn’s disease and ulcerative colitis. The
development of inflammatory bowel diseases has been linked to disruptions in the
intestinal mucosa and the reduction in gastrointestinal microbial diversity (109, 110).
Inflammatory bowel diseases are known to impact mucosal permeability in the
gastrointestinal tract and they have also been associated with an increased risk of
colorectal cancer (7, 111). Given the similarity in symptoms across different
inflammatory bowel diseases, it can often be difficult to ascertain the exact diagnosis of
individuals in a non-invasive way. Endoscopy or histologic samples are usually needed to
verify the disease in question.
A meta-analysis by Kappelman, et al., 2007, analyzed 9 million insurance health
claims and determined that the overall prevalence of irritable bowel diseases, Crohn’s
disease and ulcerative colitis, in US adults is 201 and 238 per 100,000, respectively
(112). This study also indicated that the prevalence of both Crohn’s disease and
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ulcerative colitis increase with age. Incidence of inflammatory bowel disease is higher in
western countries, despite the increasing frequency observed in areas of the developing
world such as Latin America (113).
Multiple studies have been conducted to evaluate the impact of diet on
inflammatory bowel diseases, but few have evaluated the factors associated with
symptom resolution in successful trials (114). Additionally, many of these studies
conducted do not include a precise way to determine which foods are problematic during
symptom development.
1.4.5.1 Crohn’s disease
Crohn’s disease is a chronic disease that can affect any part of the digestive tract.
Diagnosis of Crohn’s disease is quite difficult due to its similarity to other diseases of the
gastrointestinal tract. Clinically, a diagnosis is normally given after endoscopic
observation of the presence of skip lesions on the digestive mucosa that appear alongside
normal-appearing tissue. These lesions affect all layers of the gastrointestinal wall (115).
Common symptoms of Crohn’s disease include weight loss, diarrhea, iron deficiency,
nausea, and vomiting (109). Often, the symptoms of Crohn’s disease can flare and retreat,
causing more difficulty in the diagnosis of the disease (108).
The exact pathogenesis of Crohn’s disease remains unknown, but it has been
demonstrated that individuals with Crohn’s disease have reduced tolerance to commensal
intestinal microorganisms (116). Crohn’s disease is characterized primarily by a TH1
immune response, with cytokines IFNγ and IL-2 being elevated in Chron’s disease
patients (117). Tumor necrosis factors (TNF) are cytokines released by multiple immune
cells that recruit immune cells and stimulate an inflammatory response (118). Success in
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using anti-TNF therapy to treat Crohn’s disease has implicated a role of the TNF protein
family in the pathogenesis of Crohn’s disease (119).
Dietary management of Crohn’s has been suggested as a possible course of
treatment for some time now, and recent studies have indicated a prevalence of food
sensitivity in individuals with Crohn’s disease as well (120-122). It has also been shown
that individuals who demonstrate long term intake of dietary fiber from fruits are at
reduced risk for Crohn’s disease (4). A retrospective study performed in 2020 examined
food-specific IgG in 355 patients diagnosed with Crohn’s disease and found that that over
50% had IgG against corn (61.10%), egg (59.45%), rice (59.18%), tomato (56.16%) and
soybean (51.23%) (120). Another trial by Riordan et al. found that individuals with
Crohn’s disease who participated in an exclusion diet could effectively manage their
symptoms, with 84% of individuals who adhered to an elemental diet displaying reduced
symptoms after two weeks (121).
1.4.5.2 Ulcerative colitis
Ulcerative colitis is similar to Crohn’s disease in symptom presentation, but they differ in
extent and pathology. Ulcerative colitis is characterized by relapsing inflammation
confined to the colonic mucosa, and patients often have bloody stool and abdominal
tenderness (123). Endoscopic evaluation is the necessary method to confirm suspected
diagnosis and extent of ulcerative colitis. Unlike in Crohn’s disease, the area surrounding
the ulcerations characteristic of ulcerative colitis often appear inflamed, despite the fact
that the depth of inflammation in ulcerative colitis is limited to the mucosa and
submucosa (124). In addition, differing from the TH1 immune response present in
Crohn’s disease, ulcerative colitis has been associated with a unique TH2 immune
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response. The response is mediated by natural killer cells that release IL-13 and have
cytotoxic effects on epithelial cells of the colon (125). Treatments for ulcerative colitis
include 5-aminosalicylic acid, a nonsteroidal anti-inflammatory drug, as well as multiple
corticosteroids used to reduce inflammation. In severe cases, anti-TNF therapy has also
shown effectiveness in treating ulcerative colitis (123).
Diet has been suggested as a mediator for ulcerative colitis since at least the 1960s
(5). A study conducted by Candy et. al. asked subjects to avoid foods that seemed to
induce symptoms, and a significant difference in remission rate was seen when compared
to control subjects (126). Evidence suggests that individuals consuming diets rich in fat
and sugar are at higher risk of acquiring ulcerative colitis (127, 128).
1.6 CONCLUSION
The relationship between food sensitivity and food-specific IgG is complex, and further
investigation into the mechanisms of IgG-mediated food sensitivity is needed. That said,
the studies discussed above indicate a link between the presence of food-specific IgG and
adverse gastrointestinal symptoms. In the following chapter, the relationship between
food-specific IgG, digestive tract alterations, and inflammation will be further explored.
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CHAPTER 2. DIFFERENCES IN LEVELS OF FOOD-SPECIFIC IGG
BETWEEN INDIVIDUALS WITH ALTERED AND UNALTERED DIGESTIVE
TRACTS
2.1

INTRODUCTION
It is currently estimated that 20% of the of people living in industrialized

countries may suffer from some type of food sensitivity or food allergy (1). Symptoms of
food sensitivity can vary widely between individuals, from atopic rash to severe
abdominal pain, and can have a substantial impact on individual wellness. Often, these
sensitivities are present in individuals who do not possess any traditional IgE-mediated
allergies.
While the mechanisms leading to the development of food sensitivity are not fully
understood, more evidence suggests that immunoglobulin G may contribute to the
development of food sensitivity, but underlying mechanisms are not fully understood.
IgG is an antibody that is crucial in the immune system processes of infection
management and inflammation regulation (2). When repeated exposure to partially
digested food proteins over time occurs, the body will begin to create IgG antibodies
against these proteins. This can occur more frequently when intestinal permeation is
increased due to disease (3). Food-specific IgG has been associated with adverse food
sensitivity reactions in individuals who do not have laboratory confirmed food allergies
(4). The American Academy of Allergy, Asthma, and Immunology (AAAAI) does not
currently recommend testing for IgG against food proteins for the diagnosis of food
allergy or intolerance (5).
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Although there is some debate about the diagnostic utility of food-specific IgG in
recognizing food sensitivities, several studies have shown positive results in using foodspecific IgG testing to reduce disease burden (6, 7). IgG mediated exclusion diets have
been identiﬁed as a promising way to manage food sensitivity symptoms including but
not limited to migraine, symptoms of irritable bowel syndrome, symptoms of Crohn’s
disease, and symptoms of ulcerative colitis (6, 8, 9). Elevated levels of food-specific IgG
have been linked with inflammatory conditions such as irritable bowel syndrome,
Crohn’s disease, ulcerative colitis, obesity, rheumatoid arthritis, and major depressive
disorder (7, 10-14). In extreme cases of gastrointestinal disorders, such as Crohn’s
disease or ulcerative colitis, progression of the disease can require surgical intervention,
sometimes in the form of an ostomy.
In the United States, there are between 750,000 and 1,000,000 individuals living
with ostomies (15). An ostomy is a surgical procedure that reroutes bodily waste from its
usual path toward an external collection system. This can happen for various reasons,
including but not limited to cancer, damage from radiation due to cancer treatment, the
escalation of a gastrointestinal disorder such as Crohn’s disease or ulcerative colitis, or
traumatic abdominal injury. Ostomates must learn to manage their diet and fecal output
system in order to maintain a normal lifestyle and can often achieve this. Many ostomates
continue to live healthy and fulfilling lives.
However, one of the largest challenges presented to ostomates post-surgery is the
readaptation to food intake (16). At the time of the procedure, many ostomates are
malnourished due to the diseases which caused the ostomy to be necessary (16).
Adequate nourishment must also be carefully monitored after surgery, as significant
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portions of digestive tract are often removed. Because of this, the diet of ostomates often
needs to be substantially altered in order to manage nutrient acquisition, absorption, and
fecal output. This can limit the dietary options available to some ostomates (17).
Furthermore, the presence of a food sensitivity can make this challenge particularly
difficult. Unfortunately, there is no current body of research evaluating food sensitivity in
ostomates.
Several methods can be used to measure serum IgG. Clinical facilities and
laboratories frequently utilize nephelometry for measuring total IgG, which analyzes
scattering of light passed through a sample. This is a popular method due to its usability
and automation. Another widely used method is microarrays, where antigens are printed
onto a small chip that are treated and analyzed to detect IgG. Microarrays are an effective
method for analyzing IgG against many antigens. However, microarrays can be quite
expensive and are therefore often not practical for use. Enzyme linked immunosorbent
assays (ELISA) are also commonly used. Antigens are bound to a microplate to which
the desired standard and sample is added. Changes in color are measured via optical
density and a standard curve is generated to predict sample concentrations.
In this study, we evaluated the presence of IgG antibodies against food-specific
antigens using ELISA techniques. This was done in individuals with altered digestive
tracts, specifically those with ostomies, alongside samples from individuals with
inflammatory conditions located along the digestive tract. This study was performed in an
effort to determine the impact of digestive tract alterations on food sensitivity. We have
also measured biomarkers of systemic inflammation and immune competency in order to
evaluate their impact on food sensitivity. The aim was to evaluate the impact of disease
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status on their presence. Our primary hypothesis was that the presence of food-specific
IgG would be indicative of events altering the gastrointestinal tract. Our study found that
individuals with some types of ostomies and inflammatory conditions of the
gastrointestinal tract are more likely to develop food-specific IgG, and that they can have
stronger responses to food antigens than those with different conditions.
2.2

MATERIALS AND METHODS
2.2.1

Acquisition of serum samples from the Nebraska Biobank

Serum samples used in this study were acquired from the Nebraska Biobank (RRID:
SCR_021024; University of Nebraska Medical Center, Omaha, NE). The program is
partially funded by the Nebraska Research Initiative (NRI) and the Center for Clinical
and Translational Research. The samples were acquired by Dr. Jacques Izard. Under
project ID 19490, the Institutional Review Board (IRB) of the University of NebraskaLincoln made the determination that this project and the use of samples did not meet the
definitions of human subject research under regulatory requirements at 45 CFR 46.102
and the project did not require IRB approval.
Biobank samples were originally collected with the consent of Nebraska Medicine
patients and consist of remaining donated blood-samples from scheduled laboratory tests.
Serum, plasma, and DNA are recovered from the samples and stored for future research
studies. De-identified data from the Electronic Health Record (EHR) such as age, race,
BMI, diagnoses, laboratory results and medications are linked to the stored samples. The
inclusion criteria for the request were for de-identified sera from individuals over the age
of 19 with specific medical diagnoses affecting the digestive tract. Diagnosis requests are
made using the tenth revision of the International Classification of Diseases (ICD-10).
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The exclusion criteria were limited to the presence of a urostomy in ostomate samples
and that no two samples from the same individual were to be included.
A total of 198 de-identified samples were selected for sampling (Table 2.1). The
received samples were from individuals with the following diagnoses: jejunostomy
(n=22), colostomy (n=18), ileostomy (n=31), Crohn’s disease (n=18), ulcerative colitis
(n=15), appendicitis (n=18), duodenitis (n=25), eosinophilic esophagitis (n=15), food
intolerance (n=18), and periodontitis (n=18). At the source, all samples were temporarily
stored at 4 ºC for 5 days, followed by long-term storage at -80 ºC at the biobank. All
samples were collected from July 2014 through September 2019.
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Table 2.1. Description of samples acquired from Nebraska Biobank
1

International Classification of Diseases, Tenth Revision (ICD10). Asterisks represent that the
preceding alphanumeric sequence may be further broken down into subcategories of the selected
ICD10 code. Here, these codes represent the individual diagnostic groups.
ICD10
code
requested1
Z93.4

Jejunostomy present (HCC)

Number of
samples
completed2
22

Z93.3

Colostomy in place (HCC)

18

Z93.2

Ileostomy present (HCC)

31

K50.0*

Crohn's Disease

18

ICD10 Code Description (Diagnostic group)

K50.00

Crohn's disease of small intestine without complication (HCC)

7

K50.012

Crohn's disease of small intestine with intestinal obstruction (HCC)

3

K50.013

Crohn's disease of small intestine with fistula (HCC)

1

K50.018

Crohn's disease of small intestine with other complication (HCC)

3

K50.019

Terminal ileitis with complication (HCC)

4

Acute appendicitis

K35.*

18

K35.20

Acute appendicitis with generalized peritonitis

1

K35.32

Acute appendicitis with rupture

2

K35.80

Acute appendicitis, unspecified acute appendicitis type

8

K35.30

Acute appendicitis with localized peritonitis

7

K29.80

Duodenitis

25

K51.0*

Ulcerative colitis

15

K51.00

Ulcerative pancolitis without complication (HCC)

12

K51.011

Ulcerative pancolitis with rectal bleeding (HCC)

3

K20.0

Eosinophilic esophagitis

15

K90.49

Food Intolerance

18

K05.30

Periodontitis

18

2

Bolded numbers refer to the total number of samples received in each diagnostic category. Nonbolded numbers are the breakdown of the number of samples received from each subcategory.

2.2.2

Food sensitivity ELISA based testing

Serum samples were analyzed using the 109 Foods Mediterranean Food Allergy IgG
ELISA kit (Catalog number: CNS14M; Eagle Biosciences, Amherst, NH) to measure the
level of IgG against 109 different foods. This was a 96 well-based ELISA kit with a few
related foods pooled in a single well, such as lemon and lime. The list of the food targets
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of the IgG detection methodology is detailed in Table 2.2. For further analysis and
clarity, tested foods were placed into 16 groups according to the United States
Department of Agriculture Food Data Central database (18).
Table 2.2. Food-specific IgG tested by 109 foods IgG ELISA
Category
Beverages
Cereal grains and pasta

Dark green vegetables
Eggs
Finfish

Fruit

Legumes and legume products

Milk

Food
Coffee
Tea
Wheat
Gluten
Buckwheat
Corn (maize)
Barley
Rice
Rye
Durum Wheat
Oat
Broccoli
Spinach
Egg White
Egg Yolk
Cod
Salmon
Sarind/Anchovy
Sea Bass
Sole
Trout/Hake
Tuna
Lemon/Lime
Melon
Apricot/Peach
Orange/Tangerine
Pineapple
Cherry
Olive
Apple
Banana
Fig
Grape Black/White
Kiwifruit
Pear
Plum
Strawberry
Watermelon
Peanut
Soya Bean
Pea
Lentil
Chickpea
Haricot/Kideny Bean
Cow's Milk
Goat's/Sheep's Milk

FDC ID
171890
174155
169725
168147
170286
170288
170284
168931
168884
169721
169705
787465
787373
172183
172184
171955
175138
175139, 174182
175142
174196
175153
173706
167746, 168155
169092
171697, 169928
169919, 169105
169124
171719
169094
171689
173944
173021
174682
168153
169118
169949
167762
167765
172430
174270
170419
172420
173756
175193
781084
171278, 170882

Category
Nuts and seeds

Other vegetables

Poultry
Red and orange vegetables

Red meat

Shellfish

Spices, herbs, and sweets

Yeasts

Food
Pistachio
Almond
Hazelnut
Chestnut
Cocoa Bean
Cola Nut
Pine Seed
Sesame Seed
Sunflower Seed
Walnut
Chilli
Courgette (Zucchini)
Onion
Garlic
Artichoke
Aubergine (Eggplant)
Cauliflower/Cabbage
Chicory
Cucumber
Fennel
Lettuce
Mushroom
Parsley
Potato
String Bean
Chicken
Turkey
Tomato
Carrot
Peppers/Capiscum
Pumpkin
Rabbit
Beef
Lamb
Pork
Oyster/Clam
Sepia/Calamar/Octopus
Crab/Lobster
Mussel
Prawn/Shrimp
Mustard
Basil
Black/White Pepper
Caper
Honey
Yeast (beer)
Yeast (bread)

FDC ID
170184
170567
170581
170164
169593
169588
170591
170150
170562
170187
170108
169291
170000
169230
169205
169228
169986, 169975
169992
168409
169385
169249
169251
170416
170026
169961
171116
171505
170457
170393
787810
168448
174347
168608
174370
167902
171978, 782757
174215, 782743, 174218
174204, 174208
174216
175179
172234
172232
170931, 170933
172238
169640
788564
175043

ELISA manufacturer instructions were as follows; 25 µl of selected serum was
diluted into 10 ml of supplied sample diluent and 100 µl was added to the food antigen
coated ELISA plate. The plate was incubated for 30 minutes. Next, the plate wells were
aspirated and washed 3 times with 425 µl of provided wash buffer with a BioTek 405 TS
plate washer (BioTek, Winooski, VT) before the addition of 100 µl of horseradish
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peroxidase conjugated goat anti-human IgG to each well. This was followed by an
additional 30-minute incubation. The plate was then aspirated and washed 4 additional
times with 425 µl of wash buffer. After washing, 100 µl of 3,3′,5,5′-tetramethylbenzidine
(TMB) substrate solution was added to the wells and allowed to incubate for 10 minutes.
After 10 minutes, 100 µl of stop solution was added, and the ELISA plate was
immediately read at wavelengths of 450 nm and 620 nm (BioTek Synergy H1, Winooski,
VT). Optical densities from the 620 nm reading were considered as background values
and were subtracted from the 450 nm optical densities prior to analysis. Once the
ELISAs were performed, the relative abundance of food-specific IgG was calculated
using the standard curve provided by the ELISA manufacturer which consisted of a 0
AU/ml standard, a 25 AU/ml standard, and a positive control. Individual responses to
foods were then extrapolated from this curve and categorically graded as 0 (negative), 1
(borderline), 2 (positive), or 3 (strong positive) based on a manufacturer supplied ranges
for use in interpretation Table 2.3. Grades of 1, 2, and 3 taken from the 109 food IgG
ELISA were summed for each individual. This number, the categorical sum, was used to
assess overall reactivity for each individual. Additionally, the number of grades of 1, 2,
and 3 per individual were included to determine the total number of food-specific IgG
present in each serum sample.
Table 2.3. Manufacturer supplied chart for assigning categorical grade to samples.

The purpose of this protocol was to examine whether the presence of an ostomy
increased the amount of food-specific IgG present or the relative abundance of all food-
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specific IgG tested in serum. Using the table provided by the manufacturer, categorical
sums were generated by adding all calculated grades of 1, 2, and 3 for each food for
every individual. In this way, the grades have been treated as Likert scale data to estimate
overall level of food-specific IgG in sample serum.
2.2.3

Quantification of total IgG in serum

Reduced levels of total serum IgG can be indicative of an immune deficiency. To
evaluate the relationship between immune-competency and food-specific IgG, we chose
to evaluate all samples for levels of total IgG to determine any associations with foodspecific IgG that may be present with immune competency.
Total serum IgG was quantified using the commercially available Human IgG
ELISA assay (Catalog number: EGG39-K01; Eagle Biosciences, Amherst, NH). The
ELISA had a sensitivity of 1.816 ng/ml and a dynamic range: 15.6 ng/ml - 500 ng/ml. To
best fit the samples to the curve, serum samples were diluted 80,000-fold by serial
dilution prior to analysis. All standards and reagents were appropriately diluted prior to
analysis according to manufacturer instruction.
For the analysis, 100 µl of all standards and samples were pipetted into microplate
wells in duplicate. The plate was covered and incubated for one hour at room
temperature. After incubation, the plate was aspirated and washed four times with 300 µl
of provided wash buffer. Next, 100 µl of horseradish peroxidase anti-IgG conjugate was
added to each well and allowed to incubate for 20 minutes in the dark. The plate was then
washed four additional times. Following washing, 100 µl of TMB solution was added to
each well and incubated in the dark for 10 minutes. Finally, 100 µl of stop solution was
added to each of the wells.
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The optical density of plate was immediately read at 450 nm. The mean absorbance of
duplicate standards and samples was calculated, and the average zero-standard optical
density was subtracted. IgG levels were categorized into groups for analysis based on
previously published data and guidelines from Michigan Health at the University of
Michigan (Ann Arbor, MI) (Table 2.4) (19, 20).
Table 2.4 Categorization of Total IgG levels
Total IgG level (mg/dL)
Category
0-299
Profoundly or significantly reduced
300-599
Moderately reduced
600-1600
Normal
>1600
Elevated
2.2.4

Quantification of total IgA in serum

Like total IgG, reduced levels of total serum IgA can indicate the presence of an immune
deficiency. We chose to evaluate all samples for levels of total IgA in order to determine
any associations with diagnosis or food-specific IgG that may be present. Total serum
IgA was quantified using the commercially available Human IgA ELISA assay (Catalog
number: HUG39-K01; Eagle Biosciences, Amherst, NH). The ELISA had a sensitivity of
6.477 ng/ml and a dynamic range: 12.5 ng/ml - 800 ng/ml. To best fit the samples to the
curve, serum samples were diluted 10,000-fold by serial dilution prior to analysis. All
standards and reagents were appropriately diluted prior to analysis according to
manufacturer instruction.
For the analysis, 100 µl of all standards and samples were pipetted into microplate
wells in duplicate. The plate was covered and allowed to incubate for 30 minutes at room
temperature. After incubation, the plate was aspirated and washed four times with 300 µl
wash buffer. Next, 100 µl of horseradish peroxidase anti-IgG conjugate was added to
each well and allowed to incubate for 30 minutes in the dark. The plate was then washed
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four additional times. Following washing, 100 µl of TMB solution was added to each
well and incubated in the dark for 10 minutes. Finally, 100 µl of stop solution was added
to each of the wells. The optical density of plate was immediately read at 450 nm. The
mean absorbance of duplicate standards and samples was calculated, and the average
zero-standard optical density was subtracted. IgA levels were categorized into groups
based on guidelines from the Mayo Clinic (Rochester, MN) and Merck & Co
(Kenilworth, NJ) (Table 2.5) (21, 22).
Table 2.5 Categorization of Total IgA levels
Total IgA level (mg/dL) Category
0-6
Deficient
7-60
Reduced
61-356
Normal
>356
Elevated

2.2.5

Determination of serum calprotectin levels

Serum calprotectin serves as a biomarker for systemic inflammation. This can be related
to the integrity of the intestinal barrier and functionality of the mucosal immune system.
For these reasons, our next goal was to evaluate the levels of serum calprotectin present
in sampled individuals. Serum calprotectin was quantified using a commercially available
Calprotectin ELISA kit (Catalog number: ab267628; Abcam, Cambridge, UK). The
ELISA had a sensitivity of 35 pg/ml and a range of 32.77 pg/ml - 8000 pg/ml. In order to
best fit the samples to the curve, serum samples were diluted 4,000-fold by serial dilution
prior to analysis. All standards and reagents were also appropriately diluted prior to
analysis according to manufacturer instruction.
For the analysis, 100 µl of all standards and samples were pipetted into microplate
wells in duplicate. The plate was then covered and incubated for 2.5 hours at room
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temperature. Following incubation, the plate was washed four times with 300 µl of wash
buffer. Next, 100 µl of biotinylated calprotectin antibody was added to the wells and
allowed to incubate for one hour while shaking gently. Following incubation, the plate
was again washed four times with 300 µl of provided wash buffer. After washing, 100 µl
of horseradish peroxidase-streptavidin conjugate was added to the wells and allowed to
incubate for 45 minutes while shaking gently. After incubation, the plate was washed
four times with 300 µl of wash buffer. After washing, 100 µl of TMB solution was added
to each of the wells and allowed to incubate for 30 minutes in the dark while shaking
gently. At the conclusion of this incubation, 50 µl of stop solution was added to each
well. The optical density of the plate was then read immediately at 450 nm. The mean
absorbance of duplicate standards and samples was calculated, and the average zero
standard optical density was subtracted.
2.2.6

Statistical Analysis
2.2.6.1 Power analysis

The software Java Applets for Power and Sample Size (University of Iowa, USA) was
used to conduct a power analysis for a one-way ANOVA comparing categorical sums
between selected diagnostic groups. The effect size was estimated to be equivalent across
sample groups and was estimated using the initial 145 samples analyzed. The best
estimate for the standard deviation within groups was sigma = 7.50. This effect size
estimate was then used in the power analysis along with alpha = 0.05 and power = 0.80.
2.2.6.2 Standard Curves
All standard curves for were calculated using the R package “drc”
(https://github.com/DoseResponse/drc) in R version 4.0.3 using RStudio for mac OS (ver.
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1.4.1103). The standard curves were plotted on a semi-log graph, with the concentration
plotted logarithmically and the optical density plotted linearly. The best-fit line was
calculated using a 4-parameter logistics curve.
2.2.6.3 Kruskal-Wallis ANOVA
Statistical differences between sample groups were analyzed using a Kruskal-Wallis
ANOVA and Dunn’s test. Typically, when performing a Dunn’s test, p-values are
corrected based on the number of pairwise comparisons made in order to adjust for
possible error. These adjustments are quite conservative, and due to the high number of
groups being tested, p-values for the Dunn’s test presented in the results section are
unadjusted unless otherwise specified.
2.2.6.4 Wilcoxon sum-rank test
Additionally, differences between ostomate and non-ostomate groups were assessed.
Differences in the number of foods present, categorical sum, total serum IgG, total serum
IgA, and total serum calprotectin were analyzed for significant differences using a
Wilcoxon rank-sum test.
2.2.6.5 Responders versus non-responders
A chi-squared test of homogeneity was used to evaluate significance in the percentage of
subjects with at least one positive value across diagnostic groups to test whether the
response frequencies are homogenous. Individuals with food-specific IgG against at least
one food have been termed as “responders” and those without “non-responders”. The
same testing method was also used to determine if this homogeneity exists between
ostomy and non-ostomy samples using the same method. To further investigate the
possible factors impacting response, a logistic regression model was used to assess the
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impact of total serum IgG, total serum IgA, and ICD10 of selection on the presence of
food-specific IgG while controlling for age and BMI. The dependent variable which
measures the likelihood of food-specific IgG presence is response. Response is equal to 1
if the serum of the individual tests positive for any food-specific IgG, otherwise it is 0.
Because the independent variable of ICD10 is discrete, a linear regression analysis is
inappropriate. The logistic regression model was used to estimate the degree to which
ICD10, total IgG, and total IgA impact the likelihood of response. Because some BMI
measurements were missing from the metadata (n=46), values have been imputed for
analysis using k-nearest neighbors methodology. All statistical significance was
determined at p-value< 0.05.
2.3

RESULTS
2.3.1

Power analysis

A statistical power analysis was performed for sample size estimation using Java Applets
for Power and Sample Size (University of Iowa, USA). This was executed at the
conclusion of the analysis of 149 samples, with regards to the overall categorical sum.
With sigma=7.5, alpha=0.05 and power=80%, the estimated sample size required was
approximately n=160 (16 samples per diagnostic category) to observe significant
differences in categorical sum between groups 80% of the time. The initial power
analysis allowed us to estimate 16 samples would need to be included in each category.
For the diagnostic groups of ulcerative colitis and eosinophilic esophagitis, only 15
samples were available.
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2.3.2

Food-specific IgG present within sample population at large

Upon completion, 81.31% of all individuals tested were found to have food-specific IgG
against at least one food. To break this down further, food-specific antibodies were
detected in 93.3% (14 out of 15 participants) of eosinophilic esophagitis patients, 86.7%
(13/15) of food intolerance patients, 88.9% (16/18) of ulcerative colitis patients, 83.3%
(15/18) of colostomates, 80.6% (25/31) of ileostomates, 80% (20/25) of duodenitis
patients, 83.3% (15/18) of appendicitis patients, 77.8% (14/18) of Crohn’s disease
patients, 77.3% (17/22) of jejunostomates, and 66.7% (12/18) of periodontitis patients.
Sampled individuals had food-specific IgG against 54 of the 109 foods tested by ELISA
(Table 2.3 from Material and Methods). The top 5 most prevalent food IgG within the
population were cow’s milk (55%), egg white (50%), wheat (36%), goat’s/sheep’s milk
(35%), and egg yolk (33%), respectively.
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Table 2.6. Percent of population with antibodies against food broken down by diagnostic category.
Food

Total

Appendicitis

Colostomy

CD1

Duodenitis

EE2

FI3

Ileostomy

Jejunostomy

Periodontitis

UC4

Cow’s Milk

55%

61%

61%

39%

56%

73%

78%

61%

41%

33%

47%

Egg White

50%

56%

33%

33%

56%

87%

61%

55%

32%

50%

40%

Wheat
Goat’s/Sheep’s
Milk

36%

28%

33%

44%

16%

60%

44%

39%

41%

33%

33%

35%

17%

33%

11%

28%

67%

72%

45%

32%

28%

20%

Egg Yolk

33%

50%

33%

17%

32%

53%

44%

39%

18%

22%

20%

Yeast (beer)

28%

22%

22%

50%

16%

13%

50%

29%

50%

6%

20%

Peanut

19%

17%

28%

11%

12%

27%

33%

19%

23%

11%

13%

Yeast (bread)

19%

11%

6%

50%

8%

0%

22%

23%

41%

6%

13%

Gluten

15%

6%

11%

6%

4%

53%

17%

19%

14%

17%

7%

Soya Bean

14%

6%

17%

11%

8%

33%

17%

16%

18%

6%

13%

Pistachio

13%

11%

17%

6%

20%

13%

17%

19%

9%

0%

13%

Mustard

13%

11%

17%

17%

8%

20%

28%

6%

5%

6%

20%

Corn (Maize)

10%

0%

11%

22%

4%

13%

0%

10%

32%

0%

0%

Pea

9%

0%

22%

6%

4%

7%

11%

10%

18%

0%

7%

Oyster/Clam

9%

17%

17%

0%

4%

13%

22%

10%

0%

0%

7%

Lemon/Lime

9%

6%

22%

11%

0%

20%

22%

6%

0%

6%

0%

Barley

8%

0%

22%

11%

0%

13%

6%

13%

14%

0%

0%

Almond

8%

6%

6%

6%

4%

20%

17%

10%

5%

6%

7%

Chick Pea

6%

0%

6%

0%

0%

7%

17%

3%

18%

0%

13%

Buckwheat

6%

0%

11%

11%

0%

7%

6%

10%

14%

0%

0%

Hazelnut
Sepia/Calamar/
Octopus

6%

0%

11%

6%

0%

13%

6%

3%

9%

6%

7%

5%

6%

6%

0%

4%

7%

6%

10%

0%

0%

7%

Melon

5%

0%

11%

6%

0%

7%

6%

3%

14%

0%

0%
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1

Haricot/Kidney
Bean

4%

0%

6%

6%

0%

0%

11%

3%

14%

0%

0%

Lentil

4%

0%

0%

6%

0%

7%

6%

3%

14%

0%

0%

Rice
Orange/
Tangerine

3%

0%

11%

0%

0%

13%

0%

0%

9%

0%

0%

3%

0%

6%

6%

0%

7%

6%

3%

0%

0%

0%

Coffee

3%

6%

0%

6%

0%

7%

6%

3%

0%

0%

0%

Chestnut

2%

0%

0%

0%

0%

13%

6%

0%

5%

0%

0%

Garlic

2%

0%

0%

0%

0%

0%

6%

3%

5%

0%

0%

Apricot/Peach

2%

0%

6%

0%

0%

7%

6%

0%

0%

0%

0%

Cherry

2%

0%

6%

0%

0%

7%

6%

0%

0%

0%

0%

Pineapple

2%

0%

11%

0%

0%

0%

0%

0%

5%

0%

0%

Rabbit

2%

6%

6%

0%

0%

0%

0%

0%

0%

0%

7%

Tomato

1%

0%

6%

0%

0%

7%

0%

0%

0%

0%

0%

Rye

1%

0%

0%

0%

0%

7%

0%

0%

5%

0%

0%

Cod

1%

0%

6%

0%

0%

0%

0%

0%

0%

6%

0%

Banana

1%

0%

0%

0%

0%

0%

0%

0%

9%

0%

0%

Courgette

1%

0%

0%

0%

0%

0%

0%

3%

0%

0%

0%

Onion

1%

0%

0%

0%

0%

0%

0%

0%

5%

0%

0%

Chilli
Blakc/White
Pepper

1%

0%

6%

0%

0%

0%

0%

0%

0%

0%

0%

1%

0%

0%

0%

0%

0%

6%

0%

0%

0%

0%

Olive

1%

0%

0%

0%

0%

7%

0%

0%

0%

0%

0%

Mussel

1%

6%

0%

0%

0%

0%

0%

0%

0%

0%

0%

Tuna

1%

6%

0%

0%

0%

0%

0%

0%

0%

0%

0%

Strawberry

1%

0%

0%

0%

0%

7%

0%

0%

0%

0%

0%

2

3

4

Crohn’s Disease, Eosinophilic esophagitis, Food intolerance, Ulcerative Colitis
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2.3.3 Food-specific IgG present between ostomates and non-ostomates
Initial analysis by Wilcoxon rank-sum test indicated no significant difference in the
number of food-specific IgG present in ostomates versus non-ostomates (p=0.38).
Upon the exclusion of milk and eggs, the difference observed between the number
of food-specific IgG present in the serum of ostomates and non-ostomates approached
significance but remained above p=0.05 (p=0.056) (Figure 2.1).
Based on three Wilcoxon rank-sum tests, no significant differences were found
among non-ostomates and jejunostomates (p=0.074), colostomates (p=0.2), and
ileostomates (p=0.5) respectively (Figure 2.2).
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Figure 2.1. Wilcoxon sum-rank test on number of food-specific IgG present in
ostomates versus non-ostomates.
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Figure 2.2. Wilcoxon sum rank test on number of food-specific IgG in different
ostomy groups compared to non-ostomates. (A) Jejunostomates versus nonostomates. (B) Colostomates versus non-ostomates. (C) Ileostomates versus nonostomates.

2.3.4 Differences in number of foods positive among diagnostic categories
Although insignificant, the previous analysis indicated a tendency for ostomates to have
higher numbers of food-specific IgG than non-ostomates. In order to further investigate
the impact of diagnosis on number of food-specific IgG present in serum, the differences
in number of foods positive between each diagnostic group were examined. We did this
using a Kruskal-Wallis ANOVA, which is a non-parametric one-way ANOVA used to
determine differences in group median.
No significant difference was observed using a Kruskal-Wallis test on all sampled
diagnoses (p=0.1). However, the presence of a significant difference in the number of
foods positive per diagnostic category was observed when excluding egg and milk
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categories (p=0.015) (Figure 2.3).
Figure 2.3. Kruskal-Wallis ANOVA on number of positive foods and diagnostic
categories.

To confirm this result, a Dunn’s test was performed post-hoc. A Dunn’s test
performs pairwise comparisons on each possible combination of diagnostic groups to
determine significant differences between group means. The Dunn’s test indicated a
significantly larger number of food-specific IgG present in the serum of those with food
intolerance versus periodontitis (p=0.001), jejunostomy versus periodontitis (p=0.002),
food intolerance versus duodenitis (p=0.002), jejunostomy versus duodenitis (p=0.006),
eosinophilic esophagitis versus periodontitis (p=0.007), ileostomy versus periodontitis
(p=0.007), Crohn’s disease versus periodontitis (p=0.014), eosinophilic esophagitis
versus duodenitis (p=0.016), ileostomy versus duodenitis (p=0.017), food intolerance
versus appendicitis (p=0.020), colostomy versus periodontitis (p=0.023), food intolerance
versus ulcerative colitis (p=0.026), Crohn’s disease versus duodenitis (p=0.032), and
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jejunostomy versus appendicitis (p=0.048). Significance values for all pairwise Dunn’s
test comparisons are presented in Table 2.7.
Table 2.7. Dunn’s test pairwise comparisons between diagnostic categories of interest
and the number of foods positive.
Appendicitis

Colostomy

CD1

Duodenitis

EE2

FI3

Ileostomy

Jejunostomy

Colostomy

0.182

CD1

0.135

0.423

Duodenitis

0.253

0.050

0.032*

EE2

0.079

0.293

0.359

0.016*

FI3

0.020*

0.125

0.169

0.002*

0.291

Ileostomy

0.109

0.417

0.496

0.017*

0.341

0.139

Jejunostomy

0.048*

0.237

0.305

0.006*

0.457

0.311

0.277

Periodontitis

0.138

0.023*

0.014*

0.304

0.007*

0.001*

0.007*

0.002*

UC4

0.492

0.199

0.151

0.258

0.091

0.026*

0.127

0.059

Periodontitis

0.145

*Indicates p≤0.05
1
Crohn’s disease
2
Eosinophilic esophagitis
3
Food intolerance
4
Ulcerative colitis
2.3.4 Differences in overall reactivity to food between ostomates and nonostomates
Based on the Wilcoxon rank-sum test, no significant differences were observed in the
categorical sums of ostomates versus non-ostomates (p=0.52). Once milk and eggs were
excluded, the difference observed between the number of food-specific IgG present in the
serum of ostomates and non-ostomates approached significance but remained above
p=0.05 (p=0.074) (Figure 2.4).
Three Wilcoxon rank-sum tests were performed on non-ostomates and
jejunostomates (p=0.1), colostomates (p=0.62), and ileostomates (p=0.19) respectively,
but no significant differences were observed (Figure 2.5).
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Figure 2.4. Wilcoxon Sum Rank on overall level of reactivity in ostomates
versus non-ostomates.

Figure 2.5. Wilcoxon sum rank test on overall level of reactivity in different
ostomy groups compared to non-ostomates. (A) Jejunostomates versus nonostomates. (B) Colostomates versus non-ostomates. (C) Ileostomates versus
non-ostomates.
A
40

B 40

Wilcoxon, p = 0.1

30

Categorical sum

Categorical sum

30

20

0

0

jejunostomy

non_ostomate
Ostomy status

Wilcoxon, p = 0.19

20

10

0

ileostomy

non_ostomate
Ostomy status

colostomy

non_ostomate
Ostomy status

30

Categorical sum

20

10

10

C 40

Wilcoxon, p = 0.62
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2.3.5

Differences in overall reactivity to food with regards to disease state

Initially, no significant difference was noted between the categorical sums of all
diagnostic groups upon analysis by Kruskal-Wallis ANOVA (p=0.072). Upon the
exclusion of egg and milk categories, it was indicated that there was a significant
difference in the categorical sum per diagnostic category (p=0.013) (Figure 2.6).
Figure 2.6. Kruskal-Wallis ANOVA on food-specific-IgG categorical reactivity and
diagnostic categories.

Again, a post-hoc Dunn’s test was performed to better evaluate which groups
were different. The Dunn’s test indicated that there was a significant difference in the
categorical sums of those with food intolerance versus periodontitis (p=0.001), food
intolerance versus duodenitis (p=0.002), jejunostomy versus periodontitis (p=0.003),
ileostomy versus periodontitis (p=0.006), Crohn’s disease versus periodontitis (p=0.007),
jejunostomy versus duodenitis (p=0.007), eosinophilic esophagitis versus periodontitis
(p=0.007), ileostomy versus duodenitis (p=0.014), Crohn’s disease versus duodenitis
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(p=0.015), eosinophilic esophagitis versus duodenitis (p=0.017), food intolerance versus
ulcerative colitis (p=0.022), Colostomy versus periodontitis (p=0.029), and food
intolerance versus appendicitis (p=0.031). Significance values for all pairwise Dunn’s test
comparisons are listed in Table 2.8.
Table 2.8. Dunn’s test pairwise comparisons between ICD10 of interest and categorical
sum.
Appendicitis

Colostomy

Colostomy

0.261

CD1

0.110

0.278

Duodenitis

CD1

EE2

Duodenitis

FI3

Ileostomy

Jejunostomy

0.200

0.063

0.015*

2

0.107

0.263

0.470

0.017*

3

0.031*

0.110

0.261

0.002*

0.296

Ileostomy

0.131

0.343

0.398

0.014*

0.372

0.164

Jejunostomy

0.073

0.216

0.433

0.007*

0.467

0.307

0.321

Periodontitis

0.105

0.029*

0.007*

0.306

0.007*

0.001*

0.006*

0.003*

0.409

0.201

0.081

0.290

0.079

0.022*

0.095

0.052

EE
FI

UC

4

Periodontitis

0.167

*Indicates p<0.05
1
Crohn’s disease
2
Eosinophilic esophagitis
3
Food intolerance
4
Ulcerative colitis
2.3.6

Testing for immunocompetence: Differences in total serum IgG with
regards to disease status

Total IgG levels in serum have been quantified and analyzed for all samples. A KruskalWallis test indicated that there were no significant differences in the levels of total serum
IgG between groups tested (p=0.66) (Figure 2.7). In addition, ostomate groups were
compared with non-ostomates using the Wilcoxon rank-sum test, and no significant
differences were observed (p=0.65) (Figure 2.8).
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Three Wilcoxon rank-sum tests on non-ostomates and jejunostomates (p=0.54),
colostomates (p=0.85), and ileostomates (p=0.90) showed that no significant differences
were observed (Figure 2.9).
Figure 2.7. Kruskal-Wallis ANOVA on diagnostic category and total serum IgG.
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Figure 2.8. Wilcoxon sum-rank test on total serum IgG of ostomates versus
non-ostomates.

Figure 2.9. Wilcoxon sum rank test on level of total serum IgG in different ostomy
groups compared to non-ostomates. (A) Jejunostomates versus non-ostomates. (B)
Colostomates versus non-ostomates. (C) Ileostomates versus non-ostomates.
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2.3.7

Relationship between total serum IgG and categorical sum

The linear regression indicated a strong positive correlation (p<0.001) between total
serum IgG and categorical sum, suggesting that elevated levels of total IgG are associated
with higher levels of reactivity to food-specific IgG (Figure 2.10). This correlation was
maintained even after removing the outlier data point (p<0.001).
Figure 2.10. Linear regression of total serum IgG versus categorical sum.

The relationship between total IgG and categorical sum was further explored by
looking at categorical ranges of IgG levels to evaluate whether specific ranges were
statistically different. Individuals were put into four groups to indicate IgG status:
"profoundly or significantly reduced", "mild-moderately reduced", "normal", and
"elevated" (Figure 2.4) The Kruskal-Wallis ANOVA indicated that there were significant
differences between the groups (p=0.002) (Figure 2.11). A post-hoc Dunn’s test was
performed, and significant pairwise differences were observed between elevated and
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mild-moderately reduced (p=0.03), mild-moderately reduced and normal (p=0.04),
elevated and profoundly or significantly reduced (p=0.014), and normal and profoundly
or significantly reduced (p=0.019). P-value adjustments were made using the BenjaminiYeukateli adjustment.
Figure 2.11. Kruskal-Wallis ANOVA on total serum IgG level versus categorical sum.

2.3.8

Serum calprotectin quantitation in context of disease status

Serum calprotectin levels in samples were quantified and analyzed for all samples. A
Wilcoxon rank-sum test indicated that no significant differences were present between
ostomates and non-ostomates (p=0.92) (Figure 2.12). Additionally, a Kruskal-Wallis test
indicated that there were no significant differences in the levels of serum calprotectin
between groups tested (p=0.72) (Figure 2.13).
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Figure 2.12. Wilcoxon sum rank test on serum calprotectin in ostomates
versus non-ostomates.
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Figure 2.13. Kruskal-Wallis ANOVA on total serum calprotectin.

2.3.9

Testing for immunocompetence: Differences in total serum IgA with
regards to disease status

Total IgA levels in serum were quantified and analyzed for all samples. A Kruskal-Wallis
test indicated that there were no significant differences in the levels of total serum IgA
between groups tested (p=0.74) (Figure 2.14). In addition, ostomate groups were
compared with non-ostomates using the Wilcoxon rank-sum test, and no significant
differences were observed (p=0.56) (Figure 2.15).
We further refined analysis by comparing each individual ostomate category to
non-ostomates (Figure 2.16). Three Wilcoxon rank-sum tests were performed on nonostomates and jejunostomates (p=0.93), colostomates (p=0.6), and ileostomates (p=0.2)
respectively. No significant differences were observed.
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Figure 2.14. Kruskal-Wallis ANOVA on diagnostic category and total serum IgA.

Figure 2.15. Wilcoxon sum-rank test on total serum IgA of ostomates
versus non-ostomates.
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Figure 2.16. Wilcoxon sum rank test on level of total serum IgA in different ostomy
groups compared to non-ostomates. (A) Jejunostomates versus non-ostomates. (B)
Colostomates versus non-ostomates. (C) Ileostomates versus non-ostomates.

2.3.10 Relationship between total serum IgA and categorical sum
The relationship between total IgA and categorical sum was explored by looking at
categorical ranges of IgA levels to evaluate whether specific ranges were statistically
different. Individuals were put into four groups to indicate IgA status: "deficient",
"reduced", "normal", and "elevated" (Table 2.5). A Kruskal-Wallis ANOVA was
performed and indicated that there were no significant differences between the groups
(p=0.56) (Figure 2.17).
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Figure 2.17. Kruskal-Wallis ANOVA on total serum IgA level versus categorical sum.

2.3.11 Probability of response based on age, BMI, total serum IgG, total
serum IgA, and ICD10
Initially, a chi-square test was performed to evaluate the homogeneity of responders
versus non-responders between the diagnostic groups, but no significance was observed.
The regression model predicts the probability of a binary dependent variable in
terms of the log odds, as a linear combination of a set of independent variables. We have
used age of the individual, BMI, total serum IgG, total serum IgA, and ICD10 (Table
2.9). Because no group differences or relationship to categorical sum were seen when
evaluating calprotectin levels, it has been excluded from the regression. In this model, the
presence of eosinophilic esophagitis, an ileostomy, a jejunostomy, and food intolerance
were found to be significantly influential factors in predicting the presence of food-
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specific IgG, with odds ratios of 6.68, 5.58, 10.4, and 16.7, respectively. This indicates
that ileostomates were 5.88 times as likely to have food-specific IgG than individuals
with periodontitis, when controlling for age, BMI, and other diagnoses. In a similar
fashion, individuals with eosinophilic esophagitis were 6.68 times more likely to have
food-specific IgG than those with periodontitis, jejunostomates were 10.4 times more
likely to have food-specific IgG than those with periodontitis, and individuals diagnosed
with food intolerance were 16.7 times more likely to have food-specific IgG. Total serum
IgG levels were broken into four categories to assess the ranges of values that are
associated with the presence of food-specific IgG. Individuals with profoundly or
significantly reduced and mild-moderately reduced levels of serum IgG were less likely
to develop food-specific IgG, with odds ratios of 0.11 and 0.38, respectively. IgA levels
were broken down into categories for the same purpose, however no significance was
observed.
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Table 2.9 Logistic regression model of predictors of food-specific IgG presence
Characteristic
OR1 95% CI2
p-value
(Intercept)
0.27 0.03, 2.11
0.22
age_years
1.01 0.99, 1.03
0.24
bmi
1.03 0.97, 1.10
0.39
IgAstatus
normal
1
—
deficient
1.81 0.14, 46.5
0.66
reduced
0.38 0.07, 2.06
0.25
elevated
0.42 0.16, 1.05
0.063
IgGstatus
normal
1
—
profoundly or significantly reduced 0.11 0.03, 0.38
<0.001
mild-moderately reduced
0.38 0.18, 0.79
0.01
elevated
4.21 0.64, 83.9
0.2
ICD10
Periodontitis
1
—
Ulcerative Colitis
2.04 0.46, 9.74
0.36
Duodenitis
2.4 0.58, 10.5
0.23
Colostomy
2.69 0.59, 13.2
0.21
Appendicitis
2.86 0.69, 12.8
0.15
Crohn's Disease
4.44 1.03, 21.5
0.052
Eosinophilic Esophagitis
6.68 1.34, 39.5
0.026
Ileostomy
5.88 1.55, 24.7
0.011
Jejunostomy
10.4 2.26, 56.8
0.004
Food Intolerance
16.7 2.95, 143
0.003
AIC = 249.73
1
OR = Odds Ratio
2
CI = Confidence Interval
2.4

DISCUSSION

Sera used for testing were acquired in September of 2019 from the Nebraska Biobank. Of
the 198 sera analyzed, 161 exhibited food-specific IgG against at least one food antigen.
Previous studies done on the presence of food-specific IgG in serum of individuals with
Crohn’s disease, ulcerative colitis, and irritable bowel syndrome have indicated that both
healthy controls and diseased individuals have high levels of milk and egg specific IgG
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(11, 23, 24). This was further validated in our study, as 55%, 50%, and 36% of our
population tested positive for IgG against cow’s milk, egg white, and wheat respectively
(Table 2.4). Therefore, we excluded categories of milk and eggs in analyses. The food
categories with the highest prevalence of food-specific IgG were Eggs, Milk, Cereal
Grains and Pasta, Yeast, and Legumes and Legume products. Coincidentally, these
categories also include foods known to be common trigger foods in IgE mediated allergy,
such as peanut, soybean, wheat, milk, and eggs. Interestingly, only two individuals tested
positive for IgG against any type of fish, despite fish being a common IgE mediated
allergy.
While all groups had individuals with food-specific IgG, the diagnostic group
with the highest prevalence of food-specific IgG was eosinophilic esophagitis. This is in
line with studies that have described elevated levels of food-specific IgG in eosinophilic
esophagitis (25, 26). Because, most of the antigen sampling that takes place in the
digestive system occurs in the large intestine, it is somewhat surprising that eosinophilic
esophagitis displayed the highest prevalence of food-specific IgG (27). This also makes it
more predictable that individuals with periodontitis exhibited the lowest prevalence of
food-specific IgG. Multiple studies have found that increased inflammation in the
digestive tract can have a deleterious effect on the barrier provided by the gastrointestinal
lining (28-30). Because of this, it is not surprising that we find food-specific IgG in all
our inflammatory controls. Despite this, no differences were observed in total
calprotectin levels between our sample groups (Figure 2.13).
Because ostomy surgery can be caused by damage to the digestive tract associated
with higher levels of intestinal permeation, an increase in exposure of the immune system

85
to food antigens would occur in ostomates. The data collected suggests that ostomates do
tend to exhibit food-specific IgG to higher numbers of foods and display higher levels of
overall reactivity than non-ostomates, however the difference was not statistically
significant (Figure 2.1, Figure 2.4). Of note, is that diagnoses which occur in the
proximal digestive tract, except for eosinophilic esophagitis, tend to display a lower
number of foods positive and a lower level of overall reactivity by way of categorical
sum than their more distal counterparts further along the digestive tract. Additional
studies that examine individual diet, cause of ostomy, and extent of intestinal damage
would need to be undertaken to determine if this relationship is causal as opposed to
simply correlated.
The observation that ostomates have higher levels of food-specific IgG becomes
especially meaningful when the impact of ostomy on the likelihood of response is
considered (Table 2.9). The logistic regression analysis indicates that multiple factors
influence the likelihood of an individual to generate food-specific IgG. It suggests that
certain disease states, such as food intolerance and eosinophilic esophagitis increase the
likelihood of an individual to develop food-specific IgG. It also indicates that individuals
with certain types of ostomies may be at higher risk of developing food-specific IgG,
however additional study taking the cause of the ostomy into consideration is necessary
to ascertain the reason for this relationship.
The analysis also indicates that individuals with reduced levels of total IgG are
less likely to produce food-specific IgG against the foods tested. One possible reason for
this could be that the presence of an immunodeficiency could result in a weaker response
to antigens sampled in the lumen of the digestive tract. Our study attempted to address
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this concern by examining levels of total IgA in the sample population, however the
logistic regression did not indicate that IgA level had a significant impact on the
development of food-specific IgG. Additionally, no significant differences were seen in
IgA levels between diagnostic groups (Figure 2.14).
2.5

CONCLUSION

This study has shown that individuals with jejunostomies and ileostomies, as well as
those with food sensitivity, eosinophilic esophagitis, and Crohn’s disease have foodspecific IgG against a greater number of foods and at a higher level than individuals with
periodontitis, duodenitis and appendicitis. Additionally, it was shown that IgG levels and
disease status can have a significant impact on the development of food-specific IgG. In
doing so, it has broadened the context for examining food sensitivity in individuals with
altered digestive tracts and those with established inflammatory conditions of the
digestive system to include additional immune factors that may have a role. Besides
simply comparing the differences between antigen and calprotectin levels in ostomates
and individuals with inflammatory conditions, it has demonstrated that food-sensitivity is
associated with these in a unique way. Further study on the specific roles of IgG, IgA,
inflammation, biogeography, and the intestinal microbiome are critical to untangling this
complex web of interactions between food proteins, host immune systems, and
commensal microorganisms.
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